{"DataElement":{"publicId":"3185154","version":"1","preferredName":"Salvage Therapy Receive Type","preferredDefinition":"a subdivision related to receiving treatment that is given after the cancer has not responded to other treatments.","longName":"3185128v1.0:3185131v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3185128","version":"1","preferredName":"Salvage Therapy Receive","preferredDefinition":"information related to receiving treatment that is given after the cancer has not responded to other treatments.","longName":"2177011v1.0:2241679v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177011","version":"1","preferredName":"Salvage Therapy","preferredDefinition":"Treatment that is given after the cancer has not responded to other treatments.","longName":"Salvage Therapy","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Salvage Therapy","conceptCode":"C15359","definition":"Performing a salvage procedure is the last resort. The clinical situation involves either ongoing life support measures, life support measures for more than 60 seconds during the prior 10 minutes, or unanticipated institution of extracorporeal circulatory support. (ACC)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AD8-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241679","version":"1","preferredName":"Received","preferredDefinition":"Received; taken, gotten, or acquired.","longName":"C25639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-2368-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-09","modifiedBy":"ONEDATA","dateModified":"2005-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E27DE-031C-E466-E040-BB89AD430E6E","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3185131","version":"1","preferredName":"Salvage Therapy Received Type","preferredDefinition":"a subdivision of a particular kind of thing for salvage therapy received.","longName":"3185131v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4E27DE-0350-E466-E040-BB89AD430E6E","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"RAF265","valueDescription":"RAF265","ValueMeaning":{"publicId":"3185320","version":"1","preferredName":"RAF265","longName":"3185320","preferredDefinition":"RAF265","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A602691-7F77-B189-E040-BB89AD437FA7","latestVersionIndicator":"Yes","beginDate":"2011-01-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A602691-7F90-B189-E040-BB89AD437FA7","beginDate":"2011-01-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-21","modifiedBy":"ONEDATA","dateModified":"2011-01-21","deletedIndicator":"No"},{"value":"PLX4032 (RG7204; RO5185426)","valueDescription":"PLX4032 (RG7204; RO5185426)","ValueMeaning":{"publicId":"3185132","version":"1","preferredName":"PLX4032 (RG7204; RO5185426)","longName":"3185132","preferredDefinition":"PLX4032 (RG7204; RO5185426)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2A8-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4E41E5-A2C1-57BF-E040-BB89AD4327A8","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Interferon-alpha","valueDescription":"Interferon Alpha","ValueMeaning":{"publicId":"3185133","version":"1","preferredName":"Interferon Alpha","longName":"3185133","preferredDefinition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon Alpha","conceptCode":"C20494","definition":"A class of interferon (leukocyte interferon) produced predominantly by B lymphocytes.  Located in a cluster on 9p22 there are at least 13 functional genes and 1 pseudogene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2CB-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4E41E5-A2E3-57BF-E040-BB89AD4327A8","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Ipilimumab","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4E41E5-A30A-57BF-E040-BB89AD4327A8","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"Tremelimumab","valueDescription":"Tremelimumab","ValueMeaning":{"publicId":"3185137","version":"1","preferredName":"Tremelimumab","longName":"3185137","preferredDefinition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tremelimumab","conceptCode":"C49085","definition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A317-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4E41E5-A330-57BF-E040-BB89AD4327A8","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"},{"value":"GSK2118436","valueDescription":"BRAF Inhibitor GSK2118436","ValueMeaning":{"publicId":"3185139","version":"1","preferredName":"BRAF Inhibitor GSK2118436","longName":"3185139","preferredDefinition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. BRAF inhibitor GSK2118436 selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dabrafenib","conceptCode":"C82386","definition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A33D-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A4E41E5-A356-57BF-E040-BB89AD4327A8","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ONEDATA","dateModified":"2011-01-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A292-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ALAIS","dateModified":"2011-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Did the patient receive any o","type":"Preferred Question Text","description":"Did the patient receive any of the following as part of salvage therapy","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9A4E27DE-032E-E466-E040-BB89AD430E6E","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"ALAIS","dateModified":"2011-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}